MAPS pursued a lengthy FDA approval process, hoping mainstream acceptance of MDMA therapy could positively impact access to other treatments.

[7] Over decades, MAPS collaborated with scientists, raised funds through philanthropic means, and worked to change public perceptions of psychedelics.

Four years after Meaghan Buisson submitted a formal complaint to MAPS regarding the series of incidents, Doblin defended the organisation failing to review all videos of the sessions, stating "This unethical sexual misconduct happened after the therapy was over … So that made us think that we didn't need to review the video.

"[8] An independent advisory panel of the Food and Drug Administration rejected the use of MDMA-assisted therapy for post-traumatic stress disorder on June 4, 2024.

Brian Pace, a lecturer in plant pathology at Ohio State University, criticized Mr. Doblin’s public comments, including a belief that legalizing and regulating them would bring about world peace.